— Sage Therapeutics (NASDAQ: SAGE) reported fourth quarter 2019 loss of $3.25 per share vs. expected loss per share of $3.61.
— Total revenue stood at $1.96 million vs. $3.68 million expected.
— Sage expects revenue growth of ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD), will be modest over the next couple of quarters with an increase in the rate of growth of ZULRESSO revenue anticipated in the second half of 2020.
— The company will be having a meeting with the FDA in the first quarter of 2020 to discuss about Zuranolone, the clinical program for the treatment of major depressive disorder (MDD) and PPD.
— R&D expenses were $91.3 million compared to $88.8 million in the prior-year quarter. SG&A expenses were $85.1 million vs. $75.7 million in the fourth quarter of 2018.
— SAGE stock, which ended down 1.24% at $63.65, had dropped 12% so far this year.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
AAPL Earnings: Apple’s Q2 sales and profit beat estimates; iPhone sales down 10%
Apple Inc. (NASDAQ: AAPL) on Thursday reported better-than-expected profit and revenue for the second quarter of 2024. There was a 10% decrease in iPhone sales. The gadget giant reported revenues
Shopify (SHOP) is all set to report Q1 2024 results. Here’s what to expect
Over the years, Shopify Inc. (NYSE: SHOP) has steadily expanded its footprint in the online retail market through constant innovation, like the recent launch of a mobile POS device for
eBay (EBAY): A look at how the ecommerce company fared in Q1 2024
Shares of eBay Inc. (NASDAQ: EBAY) were down over 2% on Thursday. The company reported its earnings results for the first quarter of 2024 a day ago, with revenue and